Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: February 2010
-
By James DeGiulio — On December 4, 2009, the European Competitiveness Council unanimously adopted a legislative package designed to create a single EU patent and EU patent court. In a press release issued by the Council of the EU, the Council concluded that enhancing the patent system in Europe is a necessary prerequisite for…
-
Are the Courts or the FTC Misapplying the Law? By Kevin E. Noonan — In its report on so-called "pay for delay" settlements of ANDA litigation (otherwise known as "reverse payments"), the Federal Trade Commission (FTC) is calling for an outright ban on such agreements. Settlements containing "reverse payments" involved payments from the patent-…
-
By Suresh Pillai — Lupin Claims Tri-Cyclen® Patent Invalid Lupin Pharmaceuticals Inc. has filed counterclaims in its suit with Ortho-McNeil-Janssen Pharmaceuticals Inc., alleging that Ortho's patent covering its Tri-Cyclen® Lo contraceptive, U.S. Patent No. 6,214,815, is invalid. In its complaint, filed on January 15, 2010 in the U.S. District Court for the District of…
-
By Sarah Fendrick — In a press release issued last week, the U.S. Patent and Trademark Office noted that the examiner "count system" changes announced on September 30, 2009 (see "USPTO Proposes Changes to Count System") have now gone into effect. The count system is the "methodology for determining the amount of time in…
-
Are the Courts or the FTC Misapplying the Law? By Kevin E. Noonan — In its report on so-called "pay for delay" settlements of ANDA litigation (otherwise known as "reverse payments"), the Federal Trade Commission (FTC) is calling for an outright ban on such agreements. Settlements containing "reverse payments" involved payments from the patent-…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Bayer Schering Pharma AG et al. v. Lupin Ltd. et al.1:10-cv-00378; filed February 18, 2010 in the District Court of Maryland • Plaintiffs: Bayer Schering Pharma AG; Bayer Healthcare Pharmaceuticals Inc.; Schering Corp.• Defendants: …
-
February 24-25, 2010 – 2nd Expert Forum on ITC Litigation & Enforcement (American Conference Institute) – New York, NY March 1-2, 2010 – 4th Annual Patent Law Institute (Practising Law Institute) – New York, NY March 2, 2010 – Biotechnology/Chemical/Pharmaceutical (BCP) Customer Partnership Meeting (U.S. Patent and Trademark Office) – 10:00 am – 4:00 pm…
-
The U.S. Patent and Trademark Office has announced the agenda for the next biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting to be held on March 2, 2010. The proposed agenda is as follows: Morning Session • Greetings and Overview (10:00 – 10:15 am EDT): George Elliott and Remy Yucel, Directors, Technology Center 1600 • Best Practice in…
-
The Connecticut, New Jersey, New York, and Philadelphia Intellectual Property Law Associations will be holding their 26th Annual Joint Patent Practice Seminar on April 29, 2010 in New York, NY. The seminar will consist of five panels: Litigation, Pharmaceuticals/Life Sciences, Ethics, Licensing/Foreign Practice/ITC, and the USPTO, with each panel addressing a series of cases and…
-
The Board of Patent Appeals and Interferences (BPAI) will be holding its First Annual Board Conference on April 7, 2010 in Alexandria, VA. The conference will include presentations on the following topics: • State of the Board — Chief Judge Michael Fleming • A View Behind the Curtain — Vice Chief Judge James Moore, Vice…
Patent Docs 